Study identifier:D6810C00002
ClinicalTrials.gov identifier:NCT07789483
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Phase 3
No
ALXN2220
All
1180
Interventional
N/A
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2026 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: ALXN2220 Eligible participants will receive ALXN2220 administered IV q4w for a minimum of 12 months and up to 24 months or until participant has access to commercially available ALXN2220 for ATTR-CM, whichever occurs first. | - |